CA2859573A1 - Angiotensins for treatment of fibrosis - Google Patents

Angiotensins for treatment of fibrosis Download PDF

Info

Publication number
CA2859573A1
CA2859573A1 CA2859573A CA2859573A CA2859573A1 CA 2859573 A1 CA2859573 A1 CA 2859573A1 CA 2859573 A CA2859573 A CA 2859573A CA 2859573 A CA2859573 A CA 2859573A CA 2859573 A1 CA2859573 A1 CA 2859573A1
Authority
CA
Canada
Prior art keywords
acide
resin
prepreg
angiotensin
une
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2859573A
Other languages
English (en)
French (fr)
Inventor
Paul BERINGER
Richard Franklin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Southern California USC
Tarix Pharmaceuticals Ltd
Original Assignee
University of Southern California USC
Tarix Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Southern California USC, Tarix Pharmaceuticals Ltd filed Critical University of Southern California USC
Publication of CA2859573A1 publication Critical patent/CA2859573A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/085—Angiotensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Reinforced Plastic Materials (AREA)
  • Peptides Or Proteins (AREA)
CA2859573A 2011-12-16 2012-12-14 Angiotensins for treatment of fibrosis Abandoned CA2859573A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161576673P 2011-12-16 2011-12-16
US61/576,673 2011-12-16
US201161579936P 2011-12-23 2011-12-23
US61/579,936 2011-12-23
PCT/US2012/069930 WO2013090833A1 (en) 2011-12-16 2012-12-14 Angiotensins for treatment of fibrosis

Publications (1)

Publication Number Publication Date
CA2859573A1 true CA2859573A1 (en) 2013-06-20

Family

ID=48613248

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2859573A Abandoned CA2859573A1 (en) 2011-12-16 2012-12-14 Angiotensins for treatment of fibrosis

Country Status (9)

Country Link
US (2) US20150057216A1 (enExample)
EP (1) EP2790716A4 (enExample)
JP (1) JP2015504870A (enExample)
KR (1) KR20150028761A (enExample)
CN (1) CN104302305A (enExample)
AU (1) AU2012351939A1 (enExample)
BR (1) BR112014014674A2 (enExample)
CA (1) CA2859573A1 (enExample)
WO (1) WO2013090833A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007079139A2 (en) 2005-12-28 2007-07-12 Vertex Pharmaceuticals, Inc. Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
EP3003345A4 (en) * 2013-05-24 2017-03-01 Tarix Pharmaceuticals Ltd. Angiotensin peptides in treating marfan syndrome and related disorders
EP3016670A4 (en) 2013-07-03 2017-01-18 The Arizona Board Of Regents On Behalf Of The University Of Arizona Method for treating cognitive dysfunction
EP3142718A4 (en) * 2014-05-16 2017-11-29 Ultrast, Inc. Phase-shifting formulations
WO2016014342A2 (en) 2014-07-21 2016-01-28 Arizona Board Of Regents For The University Of Arizona Ang-(1-7) derviative oligopeptides and methods for using and producing the same
US10183055B2 (en) 2014-07-21 2019-01-22 Arizona Board Of Regents On Behalf Of The University Of Arizona Ang-(1-7) derivative oligopeptides for the treatment of pain and other indications
RU2749213C2 (ru) 2014-10-07 2021-06-07 Вертекс Фармасьютикалз Инкорпорейтед Сокристаллы модуляторов регулятора трансмембранной проводимости при кистозном фиброзе
MA41120A (fr) * 2014-12-02 2017-10-10 Afimmune Ltd Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci
HK1256423A1 (zh) 2015-07-30 2019-09-20 Monash University 纤维化治疗
JP2018530590A (ja) * 2015-10-14 2018-10-18 タリックス ファーマシューティカルズ リミテッド 表皮水疱症の処置のための方法及び組成物
WO2017218623A1 (en) * 2016-06-14 2017-12-21 Tarix Orphan Llc Methods and compositions for the treatment of epidermolysis bullosa
EP3655008A4 (en) * 2017-07-17 2021-04-07 Monash University ANGIOTENSIN RECEPTOR AGONISTS AND THEIR USES
GB201913603D0 (en) * 2019-09-20 2019-11-06 Vicore Pharma Ab New compounds
WO2021164723A1 (en) * 2020-02-20 2021-08-26 Lee Sheau Long Ginsenoside m1 as a modulator of angiotensin regulating enzymes and its use for treating diseases or conditions including symptoms caused by coronavirus
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases
EP4085921A1 (en) * 2021-05-04 2022-11-09 CU-Pharmaceuticals UG Angiotensin-(1-7) in the treatment of sars-cov related diseases
EP4475843A1 (en) 2022-02-10 2024-12-18 Vicore Pharma AB Use of buloxibutid for the treatment of idiopathic pulmonary fibrosis
GB202201723D0 (en) 2022-02-10 2022-03-30 Vicore Pharma Ab New use
WO2025050228A1 (es) * 2023-09-08 2025-03-13 Pontificia Universidad Católica De Chile Composición farmacéutica que comprende un péptido o una combinación de péptidos agonistas de los receptores mas, at1 y at2
KR102743940B1 (ko) 2023-10-06 2024-12-19 엠브릭스 주식회사 안지오텐신 전환효소 2 및 Fc 절편을 포함하는 나노디스크 및 이의 용도

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6165978A (en) * 1997-12-12 2000-12-26 University Of Southern California Wound healing composition
YU78601A (sh) * 1999-05-05 2005-07-19 Aventis Pharma Deutschland Gmbh. 1-(p-tienilbenzil)-imidazoli kao agonisti angiotenzin-(1-7)- receptora, postupak za njihovu proizvodnju, njihova primena i farmaceutski preparati koji ih sadrže
US7064127B2 (en) * 2003-12-19 2006-06-20 Mount Sinai School Of Medicine Of New York University Treatment of hepatic fibrosis with imatinib mesylate
EP2163259B1 (en) * 2008-09-12 2012-06-13 Charité-Universitätsmedizin Berlin (Charité) Use of an Ang-(1-7) receptor agonist in acute lung injury

Also Published As

Publication number Publication date
WO2013090833A1 (en) 2013-06-20
CN104302305A (zh) 2015-01-21
EP2790716A1 (en) 2014-10-22
EP2790716A4 (en) 2015-06-10
US20160074466A1 (en) 2016-03-17
US20150057216A1 (en) 2015-02-26
KR20150028761A (ko) 2015-03-16
BR112014014674A2 (pt) 2017-06-13
WO2013090833A8 (en) 2014-07-17
JP2015504870A (ja) 2015-02-16
AU2012351939A1 (en) 2014-07-10

Similar Documents

Publication Publication Date Title
CA2859573A1 (en) Angiotensins for treatment of fibrosis
US20250127717A1 (en) Compositions and methods of making brittle-matrix particles through blister pack freezing
US11026941B2 (en) Concentrated, inhalable ciprofloxacin formulation
Trapani et al. Systemic heparin delivery by the pulmonary route using chitosan and glycol chitosan nanoparticles
AU2007322224B2 (en) Dual action, inhaled formulations providing both an immediate and sustained release profile
Yang et al. Development of highly porous large PLGA microparticles for pulmonary drug delivery
KR101424518B1 (ko) 항생제 제형, 단위 투여체, 키트 및 방법
CA3027598C (en) Enhanced delivery of immunosuppressive drug compositions for pulmonary delivery
Wang et al. In vitro and in vivo performance of dry powder inhalation formulations: comparison of particles prepared by thin film freezing and micronization
WO2012148953A1 (en) Solid compositions for pharmaceutical use
JP2008503586A (ja) アンフォテリシンｂを含む組成物、方法、およびシステム
Stewart et al. Development and characterization of a dry powder formulation for anti-tuberculosis drug spectinamide 1599
JP2011513258A (ja) 改善された不純物プロファイル及び安全性を有し、吸入により投与される抗真菌薬を有するナノ懸濁液
CN113853290A (zh) 基本上平底的聚合物小瓶及其注射拉伸吹塑成型制造方法
CN115066254A (zh) 用于吸入治疗炎症性肺病的人抗炎肽
CN106456707A (zh) 干粉肽药剂
JP2008511637A (ja) 致命的な感染症を治療する薬剤組成物の増強された供給
Rocío Hernández et al. Disordered mesoporous silica particles: an emerging platform to deliver proteins to the lungs
Kole et al. Advances in spray drying technology for anti-tubercular formulation development: A comprehensive review
CN113825483A (zh) 聚合物处理袋及其制造方法
Meng et al. Nanoparticle-assisted Targeting Delivery Technologies for Preventing Organ Rejection
CN110384681A (zh) 一种用于肺纤维化的纳米制剂及其制备方法
US20220062326A1 (en) Use of materials made of cross-linked beta-cyclodextrins for the treatment of tuberculosis
Ko et al. Preparation and characterization of hyaluronic acid loaded PLGA scaffold by emulsion freeze-drying method
Kabra et al. Comparison between spray drying and freeze drying techniques for the preparation of microparticles for delivery via a dry powder inhaler to treat cystic fibrosis

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20161214

FZDE Discontinued

Effective date: 20161214